ISRCTN57835722 https://doi.org/10.1186/ISRCTN57835722

The effect of pharmacological agents on uterine junctional zone contractions during mock embryo transfer: a randomised double-blind study

Submission date
30/09/2004

Recruitment status
No longer recruiting

Registration date
30/09/2004

Overall study status
Completed

Last Edited
31/03/2020

Condition category
Pregnancy and Childbirth

[ ] Prospectively registered
[ ] Protocol
[ ] Statistical analysis plan
[ ] Results
[ ] Individual participant data
[ ] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Frank Biervliet

Contact details
Academic Department of Obstetrics & Gynaecology
Hull & East Yorkshire (NHS) Trust
The Princess Royal Hospital
Salthouse Road
Hull
United Kingdom
HU8 9HE
+44 (0)1482 701151
abc@email.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N0084096582

Study information

Scientific Title
The effect of pharmacological agents on uterine junctional zone contractions during mock embryo transfer: a randomised double-blind study

Study objectives
To assess if junctional zone contractions can be reduced by pharmacological agents.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised double-blind study

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Pregnancy and Childbirth: Embryo transfer

Interventions
The patient's baseline junctional zone contractions will be established following a 5 minute scan. Video tapes taken of both the pre and post mock embryo transfer will be assessed by two researchers who will be unaware of treatment.
20 patients allocated to the nitric oxide group, 20 to the non-steroidal anti-inflammatory group, 20 control and 20 to the COX-2 inhibitor group.

Intervention Type
Drug

Phase
Not Applicable

Primary outcome measure
1. Number of contractions per unit time
2. Speed of contractions in cm/min
3. Type of contractions
4. Speed of Echovist
5. Distance traveled by Echovist

Secondary outcome measures
Not provided at time of registration

Overall study start date
01/04/2000

Completion date
10/12/2003

Eligibility

Key inclusion criteria
Not provided at time of registration

Participant type(s)
Patient

Age group
Adult

Sex
Female

Target number of participants
80

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/04/2000

Date of final enrolment
10/12/2003

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
The Princess Royal Hospital
Hull
United Kingdom
HU8 9HE

Sponsor information

Organisation
Department of Health

Sponsor details
Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL

Sponsor type
Government

Website
http://www.dh.gov.uk/Home/fs/en

Funder(s)

Funder type
Research organisation

Funder Name
The North and South Bank Research and Development Consortium (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration